The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis

Abstract

BackgroundThis study investigated the relationship between changes in lung function (as measured by forced expiratory volume in one second [FEV1]) and the St. George’s Respiratory Questionnaire (SGRQ) and economically significant outcomes of exacerbations and health resource utilization, with an aim to provide insight into whether the effects of COPD treatment on lung function and health status relate to a reduced risk for exacerbations.MethodsA systematic literature review was conducted in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials to identify randomized controlled trials of adult COPD patients published in English since 2002 in order to relate mean change in FEV1 and SGRQ total score to exacerbations and hospitalizations. These predictor/outcome pairs were analyzed using sample-size weighted regression analyses, which estimated a regression slope relating the two treatment effects, as well as a confidence interval and a test of statistical significance.ResultsSixty-seven trials were included in the analysis. Significant relationships were seen between: FEV1 and any exacerbation (time to first exacerbation or patients with at least one exacerbation, p = 0.001); between FEV1 and moderate-to-severe exacerbations (time to first exacerbation, patients with at least one exacerbation, or annualized rate, p = 0.045); between SGRQ score and any exacerbation (time to first exacerbation or patients with at least one exacerbation, p = 0.0002) and between SGRQ score and moderate-to-severe exacerbations (time to first exacerbation or patients with at least one exacerbation, p = 0.0279; annualized rate, p = 0.0024). Relationships between FEV1 or SGRQ score and annualized exacerbation rate for any exacerbation or hospitalized exacerbations were not significant.ConclusionsThe regression analysis demonstrated a significant association between improvements in FEV1 and SGRQ score and lower risk for COPD exacerbations. Even in cases of non-significant relationships, results were in the expected direction with few exceptions. The results of this analysis offer health care providers and payers a broader picture of the relationship between exacerbations and mean change in FEV1 as well as SGRQ score, and will help inform clinical and formulary-making decisions while stimulating new research questions for future prospective studies.

Does the 2017 revision improve the ability of GOLD to predict risk of future moderate and severe exacerbation?

“…And 20% of these patients were hospitalized within the next year due to exacerbation. These findings confirm the previous studies which showed that exacerbation risk correlates with FEV 1 …”

Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis

“…ICS had a protective effect on all individual CID components, indicating that the benefit offered by BUD extends beyond the effect on exacerbations, and includes prevention of deteriorations in lung function and QoL. This contrasts with the modest effect of ICS when assessing improvements in FEV 1 and SGRQ previously reported with ICS [13], suggesting that ICS in COPD are primarily preventive and protective, rather than to induce improvements in lung function and QoL only. Patients who experienced a CID within Fig.…”

Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life

“…Therefore, patients should be monitored until they have fully recovered from their COPD exacerbation [49]. While a long symptom duration during a COPD exacerbation was associated with an increased risk of further exacerbations [45], a fast recovery in lung function following treatment has been shown to be significantly associated with a lower risk for COPD exacerbations [50].…”

“…However, even a mild COPD exacerbation can adversely impact patient health-related quality of life [53]. Conversely, a better health-related quality of life has been associated with a lower risk for COPD exacerbations [50].…”